Back to Home
    Research & Industry

    ESMO Immuno-Oncology & Advanced Therapies Congress 2026: What to Know About December's London Gathering

    By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
    November 5, 20264 min read
    ESMO Immuno-Oncology & Advanced Therapies Congress 2026: What to Know About December's London Gathering

    What this article covers

    Key Dates and Location
    The congress runs December 14–16, 2026, at the Queen Elizabeth II Centre in London, United Kingdom. It is organized by ESMO, one of the two largest medical oncology societies in the world (alongside the American Society of Clinical Oncology), and is held both onsite and online.
    What the Event Covers
    Unlike ESMO's flagship Congress, which spans all of oncology, this meeting is narrowly built around immune-based cancer treatment. According to event listings, the program is designed to cover "the entire spectrum from basic science to translational research and clinical development" in immuno-oncology.
    Who Attends
    ESMO describes the meeting's audience as specialists in cancer immunotherapy — medical oncologists, translational researchers, and industry and regulatory stakeholders — rather than a general-interest or patient-facing event. It draws a more specialized crowd than ESMO's October Congress, reflecting how much the immuno-oncology field has grown into its own distinct subspecialty over the past decade.
    Why It Matters for Patients and Families
    Conferences like this one are where incremental, sometimes consequential, shifts in immunotherapy research first surface publicly — new combination data, early biomarker findings, or updated guidance on managing side effects. None of that becomes a treatment recommendation the moment it is presented; results shown at a congress are typically preliminary, unreviewed by regulators, and often represent single studies rather than established practice.
    Bottom Line
    The ESMO Immuno-Oncology & Advanced Therapies Congress 2026 is a real, confirmed, specialist-focused meeting — December 14–16 in London — that offers a useful window into where cancer immunotherapy research is actively moving, from bispecific antibodies to cellular therapies for solid tumors. As with any conference, what gets presented there is research in progress, not a finished or approved treatment, and readers should treat early data presented in December as a signal to watch rather than a guide to what is currently available or proven.

    In mid-December 2026, the European Society for Medical Oncology (ESMO) will convene its annual Immuno-Oncology & Advanced Therapies Congress in London — a focused, three-day meeting built entirely around cancer immunotherapy, from checkpoint inhibitors and bispecific antibodies to cellular therapies for solid tumors. This article previews what the congress covers, who typically attends, and why patients and families following immunotherapy research may want to pay attention to what comes out of it, while being clear about what a conference preview can and cannot tell readers about any individual treatment's effectiveness or availability.

    Key Dates and Location

    The congress runs December 14–16, 2026, at the Queen Elizabeth II Centre in London, United Kingdom. It is organized by ESMO, one of the two largest medical oncology societies in the world (alongside the American Society of Clinical Oncology), and is held both onsite and online. This continues an annual tradition — the 2025 edition was also held in London, at the same venue — making the Immuno-Oncology Congress ESMO's dedicated, year-end counterpart to its much larger general Congress (held in October 2026 in Madrid).

    What the Event Covers

    Unlike ESMO's flagship Congress, which spans all of oncology, this meeting is narrowly built around immune-based cancer treatment. According to event listings, the program is designed to cover "the entire spectrum from basic science to translational research and clinical development" in immuno-oncology. Based on the congress's recurring structure and this year's confirmed programming, expect sessions on:

    • Checkpoint inhibitors and emerging combination strategies
    • Bispecific antibodies, a rapidly expanding drug class in solid and blood cancers
    • Cellular therapies for solid tumors — an area where progress has lagged behind blood cancers
    • Biomarkers that predict both clinical benefit and toxicity risk in precision immunotherapy
    • Managing immune-related side effects (toxicities) from immunotherapy
    • Newer frontiers, including neoantigen-based vaccines, myeloid cells in the tumor microenvironment, single-cell and spatial biology tools, and applications of AI in immuno-oncology drug development

    A notable addition for 2026: ESMO and the Society for Immunotherapy of Cancer (SITC) — the two leading immuno-oncology societies in Europe and the US, respectively — are jointly running an educational "Primer" session on December 14, taught by SITC experts, aimed at grounding attendees in foundational immuno-oncology concepts before the main scientific sessions begin.

    Who Attends

    ESMO describes the meeting's audience as specialists in cancer immunotherapy — medical oncologists, translational researchers, and industry and regulatory stakeholders — rather than a general-interest or patient-facing event. It draws a more specialized crowd than ESMO's October Congress, reflecting how much the immuno-oncology field has grown into its own distinct subspecialty over the past decade.

    Why It Matters for Patients and Families

    Conferences like this one are where incremental, sometimes consequential, shifts in immunotherapy research first surface publicly — new combination data, early biomarker findings, or updated guidance on managing side effects. None of that becomes a treatment recommendation the moment it is presented; results shown at a congress are typically preliminary, unreviewed by regulators, and often represent single studies rather than established practice. Patients and caregivers following a specific cancer type may still find it useful to track which research groups and drug classes are presenting, since that often signals where a field is heading well before any approval follows.

    Bottom Line

    The ESMO Immuno-Oncology & Advanced Therapies Congress 2026 is a real, confirmed, specialist-focused meeting — December 14–16 in London — that offers a useful window into where cancer immunotherapy research is actively moving, from bispecific antibodies to cellular therapies for solid tumors. As with any conference, what gets presented there is research in progress, not a finished or approved treatment, and readers should treat early data presented in December as a signal to watch rather than a guide to what is currently available or proven.

    Key Questions Answered

    When and where is the ESMO Immuno-Oncology & Advanced Therapies Congress 2026?
    December 14–16, 2026, at the Queen Elizabeth II Centre in London, held both onsite and online.
    What topics will the congress cover?
    Checkpoint inhibitors and combinations, bispecific antibodies, cellular therapies for solid tumors, predictive biomarkers, immune-related toxicity management, neoantigen vaccines, spatial biology and AI in drug development.
    Does data presented at the congress mean a treatment is proven or available?
    No. Congress results are typically preliminary, unreviewed by regulators and often from single studies; they are signals to watch, not treatment recommendations.

    Sources

    • ESMO Immuno-Oncology Congress 2026 — UroToday Calendar, 2026 — https://www.urotoday.com/calendar-events/esmo-immuno-oncology-congress-2026.html
    • ESMO Immuno-Oncology & Advanced Therapies Congress 2026 — LMU Klinikum Pharmakologie Event Listing, 2026 — https://auth.lmu-klinikum.de/pharmakologie/p-esmo-immuno-oncology-amp-advanced-therapies-congress-2026-p/65d66eb8053a35d6
    • General Event Details — IQVIA CVS Solutions (EMT-26-10868), 2026 — https://cvs.solutions.iqvia.com/event/detail/EMT-26-10868
    • SITC and ESMO Announce Joint Primer Program for December 2026 — OncoDaily, 2026 — https://oncodaily.com/societies/sitc-609903
    • ESMO Immuno-Oncology Congress 2026 — Medflixs Agenda Listing, 2026 — https://www.medflixs.com/en/agenda/esmo-immuno-oncology-congress-2026/show
    • Queen Elizabeth II Centre, London — ESMO Immuno-Oncology Congress Venue Listing — OncoDaily, 2026 — https://oncodaily.com/venue/queen-elizabeth-ii-centre-in-london-united-kingdom/
    • ESMO Congress 2026 — HealthManagement.org, 2026 — https://healthmanagement.org/c/hospital/Event/esmo-congress-2026

    Related Articles

    The Review Dispatch

    Our weekly briefing on the regenerative medicine landscape, for researchers, clinicians, and investors.

    regenmedreview

    regenmedreview is an independent reference library covering stem cell therapy and cancer immunotherapy research — compiled for researchers, clinicians, and patients exploring the field.

    The information on this site is for general educational purposes only and does not constitute medical advice. Regenerative medicine treatments discussed here may not be approved or available in all jurisdictions. Always consult a licensed physician before making treatment decisions.

    © 2026 regenmedreview. All rights reserved.Independent. Unaffiliated. Reader-supported.